Company: Clonmel Healthcare Ltd.
Legal category: Prescription. GMS. Sport permitted.
Active ingredient: Acetylsalicylic acid (aspirin) 75mg.
Description: Oval, white, biconvex film-coated, gastro-resistant tablets.
Presentation: 28, €0.95.
Indications: Secondary prevention of myocardial infarction (MI), prevention of cardiovascular morbidity in stable angina pectoris, history of unstable angina pectoris (except during acute phase), prevention of graft occlusion after coronary artery bypass grafting, coronary angioplasty (except during acute phase), secondary prevention of transient ischaemic attacks (TIA) and ischaemic cerebrovascular accidents (CVA) when intracerebral haemorrhages are ruled out.
Pharmacology: Acetylsalicylic acid inhibits platelet activation; blocking platelet cyclooxygenase by acetylation, it inhibits thromboxane A2 synthesis, a physiological activating substance released by platelets and which would play a role in complications of atheromatosic lesions.
Dosage: Adult: 75-160mg once daily. TIA, CVA: 75-325mg once daily. Swallow whole. Elderly: As per adults. Children: Under 16 years, not recommended (unless benefit outweighs risk).
Contraindications: Hypersensitivity to salicylic acid compounds or prostaglandin synthetase inhibitors or to any of the excipients. Active, or history of recurrent peptic ulcer and/or gastric/intestinal haemorrhage, other kinds of bleeding (such as cerebrovascular haemorrhages), haemorrhagic diathesis, coagulation disorders (such as haemophilia, thrombocytopenia), severe hepatic/renal impairment. Pregnancy (doses ≥100mg/day during 3rd trimester). Lactation (long-term use and/or higher doses).
Special precautions: Not for use as an anti-inflammatory/analgesic/antipyretic. Not recommended: Emergency situations, menorrhagia. Caution: Surgery (including tooth extraction, consider temporary discontinuation), hypertension, history of gastric or duodenal ulcer, hemorrhagic episodes, moderate renal impairment, slight/moderate hepatic impairment (regularly perform liver function tests), dehydration. May contribute to Reye’s syndrome. Report any unusual bleeding symptoms. Withdraw treatment if gastrointestinal (GI) bleeding or ulceration occurs. Elderly (GI bleeding and perforation may be fatal; review regularly if prolonged therapy required). May promote bronchospasm, asthma attacks and other hypersensitivity reactions. Serious skin reactions, including Steven-Johnsons syndrome, reported rarely; discontinue at 1st signs of hypersensitivity. Reduces uric acid excretion.
Drug interactions: Contraindicated: Methotrexate >15mg/week. Not recommended: Other drugs altering haemostasis (i.e. anticoagulants such as warfarin, coumarin, heparin, thrombolytics, antiplatelet agents (e.g. clopidogrel, dipyridamole), anti-inflammatory drugs, selective serotonin reuptake inhibitors (such as sertraline, paroxetine), uricosuric agents (e.g. probenecid). Caution: Drugs increasing ulceration risk (e.g. oral corticosteroids, deferasirox), antidiabeteics (sulfonylureas), digoxin and lithium, diuretics, antihypertenstives, carbonic anhydrase inhibitors (acetazolamide), systemic corticosteroids, other NSAIDs, ibuprofen, cyclospoin or tacrolimus, valproate, phenytoin, alcohol.
Adverse drug reactions: Increased bleeding tendencies, dyspepsia.
Full prescribing information and references available from Clonmel Healthcare Ltd. Telephone: (052) 6177777 Fax: (052) 6177791. E-mail: medicalinformation@clonmel-health.ie
MIMS Ireland Copyright ®